Mr. Thomas Smeenk reports

HEMOSTEMIX CLOSES $360,000 FIRST TRANCHE OF PRIVATE PLACEMENT

Hemostemix Inc. has closed the first tranche of its previously announced non-brokered private placement of units as originally disclosed on June 17, 2026. The company raised aggregate gross proceeds of $360,000 under the first tranche through the issuance of 7.2 million units at a price of five cents per unit.

Each unit consists of one common share in the capital of the company and one-half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one additional common share at a price of 12 cents per share for a period of 24 months from the closing date of the first tranche of the offering, subject to the accelerated expiry provision described below.

If, during any 10 consecutive trading days occurring after four months and one day have elapsed following the closing date of the offering, the volume-weighted average trading price of the common shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange is greater than or equal to 15 cents per common share, the company may accelerate the expiry date of the warrants to the date that is 30 days following the date on which the company issues a news release announcing the acceleration.

In connection with the first tranche of the offering, the company paid eligible finders aggregate cash finders' fees of approximately $12,400 and issued 248,000 finders' warrants. Each finder's warrant entitles the holder to purchase one common share at an exercise price of six cents per share for a period of 24 months from the closing date of the first tranche.

The proceeds of the offering are expected to be used for sales, marketing, patient acquisition, physician education and commercialization initiatives; production and manufacturing expenses associated with ACP-01 treatments; regulatory and filing fees associated with submissions to the Ministry of Health and Wellness of the Commonwealth of the Bahamas; and general working capital and corporate purposes.

Certain directors of the company participated, directly and indirectly, in the offering, which constitutes a related-party transaction within the meaning of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions) and the policies of the exchange. The company is relying upon the exemptions from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(a) of MI 61-101, respectively, on the basis that the company is not listed on a specified stock exchange and, at the time the offering was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction insofar as it involves an interested party (within the meaning of MI 61-101) in the offering exceeds 25 per cent of the company's market capitalization calculated in accordance with MI 61-101.

The offering remains subject to final acceptance by the exchange. All securities issued in connection with the first tranche of the offering are subject to a statutory hold period of four months plus one day from the closing date in accordance with applicable Canadian securities laws in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside of Canada.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapy, VesCell, an investigational autologous stem cell therapy developed to support circulation in areas affected by diseases of ischemia. VesCell is derived from a patient's own blood and evaluated through structured clinical research. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, and appears clinically relevant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI diabetes-based patient population, the University of British Coumbia and the University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years as a midpoint result.

We seek Safe Harbor.